Ozempic may have serious side effects, including thyroid cancer and problems with the pancreas, gallbladder, kidneys, and ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

The NEW DAY study evaluating Iluvien for diabetic macular edema did not meet its primary endpoint, but showed favorable ...

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

Comprehensive eye exams are vital for detecting early signs of systemic diseases like diabetes, hypertension, and high ...

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.Collectively known as GLP-1 agonists, ...

The researchers focused on a protein called hypoxia-inducible factor (HIF), which has been linked before to diabetic retinopathy and other eye diseases. In this new work, they discovered that during ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...